Phase 3 Gout Trial, Recruiting NCT05109936 Sponsor: University Hospital, Rouen Condition: Gout
Back to Gout

Phase 3 Gout Trial, Recruiting

NCT05109936
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are having a gout attack that started no more than 5 days ago, diagnosed using standard medical criteria
  • The gout attack is affecting one or more joints in your arms or legs (such as your foot, knee, or wrist)
  • This is either your first gout attack, or a new attack where you have not been taking uric acid-lowering medication for at least 6 months
  • Your blood uric acid level is at or above a certain threshold (420 µmol/l), measured within the last 10 days
  • You are 18 years old or older
  • Your kidneys are working well enough (creatinine clearance at or above 30 ml/min), measured within the last 10 days
  • You have read, understood, and signed the consent form for the study
  • You are covered by a social security scheme (French healthcare system)
  • If you are a woman who could become pregnant, you are using an effective form of contraception (such as the pill, an IUD, or tubal ligation for more than 1 month) and have a negative pregnancy test at the start and throughout the study
  • If you are a woman, you are post-menopausal, meaning your periods stopped naturally at least 12 months before joining the study

Who may not be able to join:

  • You are under 18 years old
  • You stopped taking uric acid-lowering medication less than 6 months ago
  • You have a known allergy or sensitivity to febuxostat (the study drug, sold as ADENURIC) or any of its ingredients
  • Your kidneys are not working well enough (creatinine clearance below 30 ml/min)
  • You have a liver condition shown by significantly abnormal liver test results (confirm with trial site)
  • You currently have an alcohol dependency that is untreated
  • Your gout attack started more than 5 days ago
  • You have had an organ or bone marrow transplant
  • You are currently taking certain medications, including Naproxen, mercaptopurine, azathioprine, theophylline, certain antibiotics (macrolides), certain cholesterol-lowering drugs (statins), some blood pressure medications in combination with diuretics, or certain other drugs that affect how the body processes medicines (confirm with trial site)
  • You have a rare inherited condition affecting how your body handles certain sugars, such as galactose intolerance, lactase deficiency, or glucose/galactose malabsorption
  • You have difficulty understanding the study due to a neurological condition or because French is not sufficiently understood
  • You are pregnant, likely to be pregnant, or not using effective contraception (a negative pregnancy test is required)
  • You are currently breastfeeding
  • You have a history of a serious uncontrolled heart condition (such as a heart attack, stroke, or unstable angina), or uncontrolled metabolic, hormonal, psychiatric, or cancer-related illness
  • You are currently under an administrative or legal order restricting your freedom
  • You are under legal guardianship or a court-appointed form of protection
  • You have taken part in another clinical drug trial in the month before joining this study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 0033232888265

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
University Hospital, Rouen
Registry
ClinicalTrials.gov
Start date
2 August 2023
Est. completion
1 January 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

To compare the number of days with gout at 42 days +/- 3 days (W6) in patients with an early administration of febuxostat from the acute attack compared to patients with a delayed administration of febuxostat by 6 weeks after the acute attack.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov